Mirage IV

Indication :

Mirage' IV is indicated for treatment, in adults and children, of the following infections caused by single or multiple bacteria sensitive to Meropenem as:

§ Pneumonias and Nosocomial Pneumonia

§ Urinary Tract Infections

§ Intra-abdominal Infections

§ Gynecological Infections, such as endometritis and pelvic inflammatory disease

§ Skin and Skin Structure Infections

§ Bacterial Meningitis

§ Septicemia

§ Empiric treatment, for presumed infections in adult patients with febrile neutropenia, used as monotherapy or in combination with anti-viral or anti-fungal agents

Mirage' has proved efficacious alone or in combination with other antimicrobial agents in treatment of polymicrobial infections

There is no experience in pediatric patients with neutropenia or primary or secondary immunodeficiency.

Composition :

For Mirage 1 gm; each vial contains:

Active Ingredient

Meropenem 1 gm

Inactive Ingredient:

Sodium carbonate 207.8 mg (Equivalent to 90.2 mg elemental sodium)

For Mirage 0.5 gm; each vial contains:

Active Ingredient

Meropenem 500 mg

Inactive Ingredient:

Sodium carbonate 104 mg (Equivalent to 45.1 mg elemental sodium)